DENVER, April 7, 2005 /PRNewswire-FirstCall via COMTEX/ -- Lifeline Therapeutics, Inc. (OTC Bulletin Board: LFLT), a health and nutrition company that is dedicated to extending "healthy life expectancy" through better antioxidant therapies, today announced that Dr. James D. Crapo will be joining the company's Board of Directors. Dr. Crapo brings nearly 30 years of experience in the health and science field to his new role. He served as the Chairman of Medicine at the National Jewish Medical and Research Center, from 1996, until his recent sabbatical in 2004.
National Jewish is a top-rated private institution in immunology and allergic diseases and has been rated number one nationally in pulmonary medicine by U.S. News and World Report for the past 7 years.
"We are thrilled to welcome Dr. Crapo to our Board of Directors," said Bill Driscoll, President and CEO of Lifeline Therapeutics. "His extensive work in antioxidant research, particularly with Superoxide Dismutase (SOD), will provide additional insight into fighting both oxidative stress and aging -- two key areas in which we hope to further research in an effort to better the lives of millions of people around the world."
Dr. Crapo maintains a large research program focused on the role of oxidants and anti-oxidants in the causation and treatment of diseases. He was the first scientist to extend Dr. Fridovich and Dr. McCord's (Director of Science for Lifeline Therapeutics) original discovery of SOD to mammalian models of disease. SOD is the body's most powerful natural antioxidant.
Prior to coming to National Jewish, Dr. Crapo spent over 15 years as the Chief of the Pulmonary and Critical Care Medicine Division at Duke University Medical Center. Throughout his professional career he has been active in numerous professional societies, including service on the NHLBI Advisory Council and serving as President of the American Thoracic Society and President of the Fleischner Society.
Dr. Crapo said, "I have been involved in antioxidant research for decades. Lifeline's Protandim represents a significant breakthrough that has far-reaching implications and applications. I am truly excited to be involved with such promising research and products."
Dr. Crapo has authored more than 200 original scientific publications, numerous book chapters and seven textbooks.